ICU

Rating neutralAI Memo

SeaStar Medical

As of 2026-09-03/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Q2 commercial traction confirmed, but profitability weakened • 2026-08-12

Base target: $3 / p=45% prob

Biggest risk

The pediatric market remains small, adult-AKI upside depends on trial success and FDA approval, enrollment is incomplete, losses are widening, and the $7 million cash balance raises financing and dilution risk. No reliable analyst revision or post-print target-change data is available.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

QUELIMMUNE is showing early hospital adoption, 82% year-over-year Q2 revenue growth, 91% gross margins, and expanding reimbursement infrastructure. Successful adult-AKI trial execution could create significant upside. The packet reports a $12 median target, but the analyst count is unavailable, so it is not a robust consensus signal.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-03

Base target

p=45%

Bull target

p=15%

Bear target

p=40%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ICD-10-PCS billing codes become effective
Funding and dilution overhang
Potential adult-AKI PMA submission

BearKey bullets

A negative or inconclusive trial would materially impair the adult-AKI thesis.
Cash declined to $7.0 million amid a widening quarterly net loss, creating financing and dilution risk.
FDA approval and the late-2027 PMA timetable remain conditional.

WatchKey bullets

Q2 commercial traction confirmed, but profitability weakened

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $3 (p=45%)

Target spread vs base: +160% / -48%

Scenario probabilities

Bull Target: $7 (p=15%)Base Target: $3 (p=45%)Bear Target: $1 (p=40%)

Commentary

Primary company-filed earnings materials are constructive on revenue growth, hospital additions, billing-code implementation, and trial progress, but the financial profile remains fragile. Coverage is low, social data is absent, and analyst revisions or a verified post-release market reaction are unavailable; this supports a cautious monitoring stance rather than a high-conviction bullish view.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ICD-10-PCS billing codes become effective
Funding and dilution overhang
Potential adult-AKI PMA submission

Scenarios

Bull Target (Scenario probability)

$7 / p=15% prob

Base Target (Scenario probability)

$3 / p=45% prob

Bear Target (Scenario probability)

$1 / p=40% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-12
Q2 commercial traction confirmed, but profitability weakened
Q2 2026 QUELIMMUNE revenue was approximately $0.6 million, up 82% year over year, with the customer base reaching 20 hospitals and gross margin of 91%. However, net loss widened to approximately $3.7 million and cash declined to $7.0 million from $12.0 million at year-end 2025 [#SEC-8K-2026-08-12].
Prob 85.00% • Move 10.00% • Priced-in 70.00%
EVENT2027-03-31
NEUTRALIZE-AKI enrollment completion
The pivotal adult-AKI trial had enrolled 223 of 339 patients, with completion anticipated around year-end 2026 or in Q1 2027. This is an important execution checkpoint, but enrollment pace and trial outcome remain uncertain [#SEC-8K-2026-08-12].
Prob 55.00% • Move 25.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

ICD-10-PCS billing codes become effective
2026-10-01
CMS-issued ICD-10-PCS codes for SeaStar’s SCD therapy are expected to take effect on October 1, 2026, potentially reducing an inpatient billing barrier. Adoption and revenue acceleration remain unproven [#SEC-8K-2026-08-12].
Prob 90% • Move 12% • Priced-in 45%
Funding and dilution overhang
2026-12-31
The company continues to report substantial operating losses while cash fell to $7.0 million by June 30, 2026. Additional financing could create dilution or pressure the share price [#SEC-8K-2026-08-12].
Prob 80% • Move -30% • Priced-in 75%

Long-term Catalysts

Months to a year

Potential adult-AKI PMA submission
2027-12-31
Management expects a PMA application near the end of 2027, conditional on a positive NEUTRALIZE-AKI result. The adult market opportunity is materially larger than the current pediatric market, but regulatory and clinical risk is substantial [#SEC-8K-2026-08-12].
Prob 35% • Move 70% • Priced-in 20%

Risks

A negative or inconclusive trial would materially impair the adult-AKI thesis.
Cash declined to $7.0 million amid a widening quarterly net loss, creating financing and dilution risk.
FDA approval and the late-2027 PMA timetable remain conditional.
NEUTRALIZE-AKI enrollment may slip beyond year-end 2026 or Q1 2027.
No dependable analyst-revision or post-earnings price-reaction evidence was available.
The pediatric market is limited in size, and hospital adoption may not scale as expected.

Peers

Symbol	Summary
ABT	Large-cap medtech and hospital-channel benchmark; useful for scale and balance-sheet comparison, but not a direct renal-therapy peer.
BSX	Procedure-driven medtech benchmark showing the adoption and financial strength ICU would need to achieve; adjacent rather than direct.
EW	Clinical-adoption and commercialization benchmark; materially larger and not directly comparable to ICU’s single-product, development-stage profile.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

ABT

Large-cap medtech and hospital-channel benchmark; useful for scale and balance-sheet comparison, but not a direct renal-therapy peer.

BSX

Procedure-driven medtech benchmark showing the adoption and financial strength ICU would need to achieve; adjacent rather than direct.

Clinical-adoption and commercialization benchmark; materially larger and not directly comparable to ICU’s single-product, development-stage profile.